Thiazolidinediones and PPARγ agonists: Time for a reassessment

Trends in Endocrinology and Metabolism

Volumn 23, Issue 5, 2012, Pages 205-215

  Cariou, Bertrand ^a,b,c   Charbonnel, Bernard ^b,c   Staels, Bart ^d,e  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d UNIV LILLE   (France)

^e Université Droit et Santé de Lille ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ATHEROSCLEROSIS; BLADDER CANCER; BONE REMODELING; CELL PROLIFERATION; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FLUID RETENTION; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HEART FAILURE; HEART PROTECTION; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; LACTIC ACIDOSIS; LIPID METABOLISM; LOW DRUG DOSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; MODELS, BIOLOGICAL; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84860375795     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.03.001     Document Type: Review

References (100)

1. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARγ. Annu. Rev. Biochem. 2008, 77:289-312.
2. Lehmann J.M., et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270:12953-12956.
3. Kahn S.E., et al. Glycemic durability of rosiglitazone, metformine, or glyburide monotherapy. N. Engl. J. Med. 2006, 355:2427-2443.
4. Shibuya A., et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998, 21:2140-2143.
5. Nissen S.E., Wolski K. Effects of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356:2457-2471.
6. Lewis J.D., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
7. Caisse Nationale de l'Assurance Maladie Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI http://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/pioglitazone-et-cancer-de-la-vessie.php.
8. Strauss D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28:551-558.
9. Tontonoz P., et al. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
10. Agostini M., et al. Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance. Cell Metab. 2006, 4:303-311.
11. Chao L., et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 2000, 101:1354-1361.
12. He W., et al. Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15712-15717.
13. Hevener A.L., et al. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 2003, 9:1491-1497.
14. Norris A.W., et al. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 2003, 112:608-618.
15. Sugii S., et al. PPARγ activation in adipocytes is sufficient for systemic insulin sensitization. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:22504-22509.
16. Samuel V.T., et al. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010, 375:2267-2277.
17. Yu J.G., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002, 51:2968-2974.
18. Yamauchi T., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
19. Nawrocki A.R., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists. J. Biol. Chem. 2006, 281:2654-2660.
20. Wesberg S.P., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
21. Bouhlel M.A., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007, 6:137-143.
22. Hevener A.L., et al. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest. 2007, 117:1658-1669.
23. Prieur X., et al. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 2011, 60:797-809.
24. Fajas L., et al. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 1997, 272:18779-18789.
25. Boelsterli U.A., Bedoucha M. Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes. Biochem. Pharmacol. 2002, 63:1-10.
26. Vidal-Puig A., et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 1996, 97:2553-2561.
27. Gavrilova O., et al. Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 2003, 278:34268-34276.
28. Moran-Alvado E., et al. Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte-and macrophage-specific conditional knockouts. FASEB J. 2011, 25:2538-2550.
29. Westerbacka J., et al. Genes involved in fatty acid partitioning and binding lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007, 56:2759-2765.
30. Pettinelli P., Videla L.A. Up-regulation of PPAR-γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1Cc induction. J. Clin. Endocrinol. Metab. 2011, 96:1424-1430.
31. Belfort R., et al. A placebo-controlled trial of piogliotazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006, 355:2297-2307.
32. Ratziu V., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135:100-110.
33. Tailleux A., et al. Role of PPARs in NAFLD: potential therapeutic targets. Biochim. Biophys. Acta 2011, 10.1016/j.bbalip.2011.10.016.
34. Nan Y.M., et al. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand. J. Gastroenterol. 2011, 46:358-369.
35. Galli A., et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002, 122:1924-1940.
36. Rigamonti E., et al. Regulation of macrophage function by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscleros. Thromb. Vasc. Biol. 2008, 28:1050-1059.
37. Glass C.K., Saijo K. Nuclear transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 2010, 10:365-376.
38. Li A.C., et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2000, 106:523-531.
39. Chawla A., et al. A PPARgamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 2001, 7:161-171.
40. Tontonoz P., et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93:241-252.
41. Chinetti G., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 2001, 7:53-58.
42. Li A.C., et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 2004, 114:1564-1576.
43. Zhang H., et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9406-9411.
44. Guan Y., et al. Thiazolidinediones expands body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat. Med. 2005, 11:861-866.
45. Vallon V., et al. Thiazolidinedione-induced fluid retention is independent of collecting duct αENaC activity. J. Am. Soc. Nephrol. 2009, 20:721-779.
46. Betteridge D.J. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabet. Med. 2011, 28:759-771.
47. Wan Y. PPARγ in bone homeostasis. Trends Endocrinol. Metab. 2010, 21:722-728.
48. Han S., Roman J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics ?. Anticancer Drugs 2007, 18:439-445.
49. Galli A., et al. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. Hepatology 2010, 52:493-505.
50. Suzuki S., et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol. Sci. 2010, 113:349-357.
51. Varley C.L., Southgate J. Effects of PPAR agonists on proliferation and differentiation in human urothelium. Exp. Toxicol. Pathol. 2008, 60:435-441.
52. Dominick M.A., et al. Urothelial cacinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPARalpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol. Pathol. 2006, 34:903-920.
53. Tiikkainen M., et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169-2176.
54. Miyazaki Y., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 2002, 87:2784-2791.
55. Juurinen L., et al. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses. J. Clin. Endocrinol. Metab. 2008, 93:118-124.
56. Phielix E., et al. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol. Sci. 2011, 32:607-616.
57. Basu M., et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006, 29:510-514.
58. Boardman M.K., et al. DURATION-4: Improvements in glucose control and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide once weekly, metformin, pioglitazone, or sitagliptin. Diabetologia 2011, 54(Suppl. 1):S314. (Poster 779).
59. DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
60. DeFronzo R.A., et al. Pioglitazone for diabetes prevention and impaired glucose tolerance. N. Engl. J. Med. 2011, 364:1104-1115.
61. DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia 2011, 54:487-495.
62. Rosenstock J., et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006, 29:554-559.
63. Mattoo V., et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin. Ther. 2005, 27:554-567.
64. Hanefeld M., et al. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc. Diabetol. 2011, 10:65.
65. Goldberg R.B., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
66. The TIDE trial investigators Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation randomised controlled trial. Diabetologia 2012, 55:36-45.
67. Lago R.M., et al. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129-1136.
68. Erdmann E., et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007, 30:2773-2778.
69. Eurich D.T., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335:497.
70. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 2010, 170:1191-1201.
71. Lincoff A.M., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
72. Khan M.A., et al. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002, 25:708-711.
73. Kendall D.M., et al. Thiazolidinediones: the case for early use. Diabetes Care 2006, 29:154-157.
74. Nissen S.E., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573.
75. Mazzone T., et al. Effect of pioglitazone compared to glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA 2006, 296:2572-2581.
76. Davidson M., et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008, 117:2123-2130.
77. Dormandy J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective PioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
78. Erdmann E., et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 2007, 49:1772-1780.
79. Wilcox R., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007, 38:865-873.
80. Tzoulaki I., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009, 339:b4731.
81. Ratziu V., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010, 51:445-453.
82. Sanyal A.J., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362:1675-1685.
83. Gastaldelli A., et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009, 50:1087-1093.
84. Doehner W., et al. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int. J. Cardiol. 2011, 10.1016/j.ijcard.2011.09.039.
85. European Medicines Agency, (2011) Questions and answers on the review of pioglitazone-containing medicines (Actos, Glustin, Competact, Glubrava and Tandemact). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/07/WC500109179.pdf.
86. Majima T., et al. Safety and efficacy of low-dose pioglitazone (7.5mg/day) vs standard-dose pioglitazone (15mg/day) in Japanese women with type 2 diabetes mellitus. Endocr. J. 2006, 53:325-330.
87. Zinman B., et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010, 376:103-111.
88. Rubenstrunk A., et al. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta 2007, 1771:1065-1081.
89. Henry R.R., et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135.
90. Cariou B., et al. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011, 34:2008-2014.
91. Riserus U., et al. Activation of peroxisome proliferator-activated receptor (PPAR) delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008, 57:332-339.
92. Olefsky J.M., et al. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J. Clin. Invest. 2000, 106:467-472.
93. Gregoire F.M., et al. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol. Endocrinol. 2009, 23:975-988.
94. Higgins S.L., Mantzoros C.S. The development of INT131 as a selective PPARgamma modulator: approach to a safer insulin sensitizer. PPAR Res. 2008, 2008. 936906, DOI:10.1155/2008/936906.
95. Dunn F.L., et al. Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes. J. Diabetes Complications 2011, 25:151-158.
96. Choi J.H., et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466:451-456.
97. Choi J.H., et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 2011, 477:477-481.
98. Dutchak P.A., et al. Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
99. Vergès B., et al. Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2011, 93:e44-e48.
100. Home P.D., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label, trial. Lancet 2009, 373:2125-2135.